Digital signals board
Quantified digital momentum across the six launch assets — search interest, KOL voice, congress presence, community and payer chatter.
Digital momentum league
Share of voice — 6 months
Social listening · Sep 2026KOL activity leaderboard
X / LinkedIn · Sep 2026| Asset | SoV | Active voices | WoW |
|---|---|---|---|
| Oveporexton | 31% | 214 | +2.4pts |
| Eohilia | 26% | 188 | +1.1pts |
| Fruzaqla | 24% | 173 | +0.6pts |
| Rusfertide | 18% | 96 | +1.9pts |
| Mezagitamab | 12% | 64 | +0.8pts |
| Adzynma | 9% | 41 | +0.3pts |
Community sentiment
NLP over forums · Sep 2026Adzynma
84
Eohilia
81
Oveporexton
78
Fruzaqla
74
Rusfertide
71
Mezagitamab
66
Oveporexton
81Search interest index
74idx+4pts
Congress abstracts 12m
38abstracts+2new
KOL share of voice
31%+1.8pts
News & PR velocity
26/mo+3items
Patient community volume
12.4k posts+0.6k
Eohilia
79Search interest index
68idx+4pts
Congress abstracts 12m
21abstracts+2new
KOL share of voice
26%+1.8pts
News & PR velocity
15/mo+3items
Patient community volume
18.6k posts+0.6k
Fruzaqla
71Search interest index
62idx+4pts
Congress abstracts 12m
29abstracts+2new
KOL share of voice
24%+1.8pts
News & PR velocity
18/mo+3items
Patient community volume
9.8k posts+0.6k
Rusfertide
58Search interest index
41idx+4pts
Congress abstracts 12m
24abstracts+2new
KOL share of voice
18%+1.8pts
News & PR velocity
14/mo+3items
Patient community volume
6.2k posts+0.6k
Adzynma
52Search interest index
38idx+4pts
Congress abstracts 12m
15abstracts+2new
KOL share of voice
9%+1.8pts
News & PR velocity
8/mo+3items
Patient community volume
3.4k posts+0.6k
Mezagitamab
49Search interest index
33idx+4pts
Congress abstracts 12m
17abstracts+2new
KOL share of voice
12%+1.8pts
News & PR velocity
9/mo+3items
Patient community volume
4.1k posts+0.6k